CL2004001046A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN 1er AGENTE TERAPEUTICO QUE ES UN ANTIPSICOTICO ATIPICO Y UN 2o AGENTE TERAPEUTICO SELECCIONADO DE AGENTES MODULADORES DE LOS RECEPTORES DEL GABA, AGENTES ANTICONVULSIVOS Y BENZODIAZEPINAS; USO PARA TRATAR TRA - Google Patents

COMPOSICION FARMACEUTICA QUE COMPRENDE UN 1er AGENTE TERAPEUTICO QUE ES UN ANTIPSICOTICO ATIPICO Y UN 2o AGENTE TERAPEUTICO SELECCIONADO DE AGENTES MODULADORES DE LOS RECEPTORES DEL GABA, AGENTES ANTICONVULSIVOS Y BENZODIAZEPINAS; USO PARA TRATAR TRA

Info

Publication number
CL2004001046A1
CL2004001046A1 CL200401046A CL2004001046A CL2004001046A1 CL 2004001046 A1 CL2004001046 A1 CL 2004001046A1 CL 200401046 A CL200401046 A CL 200401046A CL 2004001046 A CL2004001046 A CL 2004001046A CL 2004001046 A1 CL2004001046 A1 CL 2004001046A1
Authority
CL
Chile
Prior art keywords
therapeutic agent
agents
antipsychotic
treat
antipsytic
Prior art date
Application number
CL200401046A
Other languages
English (en)
Inventor
Steven Joseph Romano
Original Assignee
Pfizer Products Inc Sa Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33452430&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004001046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz
Publication of CL2004001046A1 publication Critical patent/CL2004001046A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION ARMACEUTICA QUE CMPRENDE UN AGENTE ANTIPSICOTICO ATIPICO, Y UN AGENTE MODULADOR DE LOS RECEPTORES DEL GABA, UNA BENZODIAZEPINA, Y/O UN FARMACO ANTICONVULSIVO. LOS KITS QUE CONTIENEN TALES COMBINACIONES PARA TRATAR PACIENTES QUE SUFREN DE TRANSTORNOS DE ANSIEDAD, TRANSTORNOS DE ESTADOS CLINICOS PSICOTICOS O TRANSTORNOS O ESTADOS CLINICOS DEL ESTADO DE ANIMO, RESISTENTE A LOS TRATAMIENTOS.
CL200401046A 2003-05-16 2004-05-13 COMPOSICION FARMACEUTICA QUE COMPRENDE UN 1er AGENTE TERAPEUTICO QUE ES UN ANTIPSICOTICO ATIPICO Y UN 2o AGENTE TERAPEUTICO SELECCIONADO DE AGENTES MODULADORES DE LOS RECEPTORES DEL GABA, AGENTES ANTICONVULSIVOS Y BENZODIAZEPINAS; USO PARA TRATAR TRA CL2004001046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47118803P 2003-05-16 2003-05-16

Publications (1)

Publication Number Publication Date
CL2004001046A1 true CL2004001046A1 (es) 2005-03-28

Family

ID=33452430

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401046A CL2004001046A1 (es) 2003-05-16 2004-05-13 COMPOSICION FARMACEUTICA QUE COMPRENDE UN 1er AGENTE TERAPEUTICO QUE ES UN ANTIPSICOTICO ATIPICO Y UN 2o AGENTE TERAPEUTICO SELECCIONADO DE AGENTES MODULADORES DE LOS RECEPTORES DEL GABA, AGENTES ANTICONVULSIVOS Y BENZODIAZEPINAS; USO PARA TRATAR TRA

Country Status (16)

Country Link
US (1) US20050004106A1 (es)
EP (1) EP1633400A2 (es)
JP (1) JP2006528676A (es)
KR (1) KR20060011873A (es)
CN (1) CN1791430A (es)
AU (1) AU2004237951A1 (es)
BR (1) BRPI0410271A (es)
CA (1) CA2525366A1 (es)
CL (1) CL2004001046A1 (es)
CO (1) CO5700793A2 (es)
MX (1) MXPA05012317A (es)
NO (1) NO20055172L (es)
RU (1) RU2005135454A (es)
TW (2) TW200509932A (es)
WO (1) WO2004100992A2 (es)
ZA (1) ZA200509252B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
PL1626721T3 (pl) 2003-05-23 2017-05-31 Otsuka Pharmaceutical Co., Ltd. Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
BRPI0507250A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
EP1871363A4 (en) * 2005-03-30 2009-01-21 Genpharm Inc COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
HUE050758T2 (hu) 2005-04-05 2021-01-28 Univ Yale Glutamátmoduláló szerek mentális rendellenességek kezelésére
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0611322A2 (pt) * 2005-05-31 2010-08-31 Orexigen Therapeutics Inc métodos e composicões para controlar distúrbios psicóticos
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
EP1948238B1 (en) * 2005-11-10 2013-08-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
ES2402522T3 (es) * 2005-11-22 2013-05-06 Orexigen Therapeutics, Inc. Composiciones y procedimientos para aumentar la sensibilidad a la insulina
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
MX2007008323A (es) * 2007-07-06 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico.
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
JP2011521973A (ja) * 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105664144B (zh) 2009-01-06 2020-08-11 加尔纳根有限责任公司 治疗或预防金黄色葡萄球菌感染以及根除或减少表面上金黄色葡萄球菌的组合物和方法
AU2010203714C1 (en) 2009-01-06 2013-12-12 Galenagen, Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
GB201004603D0 (en) 2010-03-19 2010-05-05 2Td Ltd Drill bit
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
RU2485946C2 (ru) * 2011-04-13 2013-06-27 Государственное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ выбора психофармакотерапии панического расстройства
AU2012245287B2 (en) * 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
CN103505734A (zh) * 2013-10-08 2014-01-15 湖南工业大学 包含r-氨基丁酸和抗癫痫药物的组合
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
AU2017384526B2 (en) 2016-12-20 2023-11-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
EP3735223A4 (en) * 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) 1960-08-09 New n-heterocyclic compounds
US2409754A (en) * 1946-10-22 Method for obtaining hydantoins
US2409654A (en) 1941-10-30 1946-10-22 Air Reduction Billet scarfing method and apparatus
CH449645A (de) * 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) * 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) * 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
HU182086B (en) 1979-06-01 1983-12-28 Wellcome Found Process for preparing new 1,2,4-triazine derivatives
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
LU83729A1 (fr) 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
FI106505B (fi) * 1993-09-27 2001-02-15 Nokia Networks Oy Langattoman tilaajaliittymän toteuttava radiojärjestelmä sekä tilaajalaite radiojärjestelmää varten
EP0746317B1 (en) * 1994-03-02 1998-06-10 Akzo Nobel N.V. Sublingual or buccal pharmaceutical composition
FI100077B (fi) * 1995-01-04 1997-09-15 Nokia Telecommunications Oy Johdottoman tilaajaliitännän toteuttava radiojärjestelmä
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL125951A (en) 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
EP1404342A1 (en) * 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics

Also Published As

Publication number Publication date
AU2004237951A1 (en) 2004-11-25
WO2004100992A3 (en) 2005-01-20
ZA200509252B (en) 2007-09-26
TW200509932A (en) 2005-03-16
NO20055172L (no) 2005-12-13
BRPI0410271A (pt) 2006-05-16
CA2525366A1 (en) 2004-11-25
KR20060011873A (ko) 2006-02-03
US20050004106A1 (en) 2005-01-06
EP1633400A2 (en) 2006-03-15
TW200735873A (en) 2007-10-01
CN1791430A (zh) 2006-06-21
JP2006528676A (ja) 2006-12-21
WO2004100992A2 (en) 2004-11-25
NO20055172D0 (no) 2005-11-03
CO5700793A2 (es) 2006-11-30
MXPA05012317A (es) 2006-01-30
RU2005135454A (ru) 2006-06-27

Similar Documents

Publication Publication Date Title
CL2004001046A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN 1er AGENTE TERAPEUTICO QUE ES UN ANTIPSICOTICO ATIPICO Y UN 2o AGENTE TERAPEUTICO SELECCIONADO DE AGENTES MODULADORES DE LOS RECEPTORES DEL GABA, AGENTES ANTICONVULSIVOS Y BENZODIAZEPINAS; USO PARA TRATAR TRA
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
AR032086A1 (es) Combinaciones de farmacos
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
PA8493701A1 (es) Compuestos para tratar la obesidad
GT199800021A (es) Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos.
GT200100201A (es) Derivados de pirazol para el tratamiento der enfermedades viricas.
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
GT200000019A (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc.
UY26129A1 (es) Moduladores del receptor glucocorticoide
SE9703226D0 (sv) New pharmaceutical composition
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
CL2007000916A1 (es) Uso de alcaftadina y de acido 6,11-dihidro-11-(1-metil-4-piperidiniliden)-5h-imidazo[2,1-b][3]benzazepin-3-carboxilico, sales, n-oxidos, solvatos e hidratos para tratar sintomas de alergia ocular, inflamacion ocular y sintomas nasales de alergia ocular; composiciones oftalmicas que los comprenden; su uso y kit farmaceutico.
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
NO20021035D0 (no) Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
BR0208694A (pt) Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
CR7049A (es) Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol
CL2004001425A1 (es) Compuesto derivados de bencilamida; composicion farmaceutica que lo comprende; uso para tratar o prevenir la infeccion por papilomavirus; y kit farmaceutico que lo contiene.
PA8653901A1 (es) PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS
PE20011049A1 (es) Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
AR041455A1 (es) Combinacion de un inhibidor del factor xa y clopidogrel